DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Malignant Mixed Neoplasm — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMalignant Mixed Neoplasm maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for malignant mixed neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) — PIK3CA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4JPS · 2.2 Å · ligand (2S)-N~1~-{4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl}pyrrolidine-1,2-dicarboxamide (1LT). Experimental structure, not a prediction.
What the evidence adds up to
A 42-year-old male patient developed five metachronous multiple primary malignant tumours within 16 years; the interval between each tumour shortened as the disease progressed, and multidisciplinary treatments were used until his death. A 52-year-old Korean woman had a 32-mm multicystic renal mass containing both papillary renal cell carcinoma and oncocytoma, treated by laparoscopic partial nephrectomy without perioperative complications. Carcinosarcoma, a true malignant mixed tumour, is rare and aggressive; prospective or randomised trial data are lacking, and treatment is guided by personal experience and case reviews, with most practitioners recommending aggressive surgery, radiation, and variably chemotherapy. Uterine carcinosarcoma, also called malignant mixed mullerian tumour, represents less than 5% of uterine malignancies and is now staged like carcinomas, though its clinical evolution is more aggressive than high-grade endometrial carcinoma.
Two clinical cases of multiple primary malignant neoplasms (solid tumours and haematopoietic malignancies) were treated using elastomeric microinfusion pumps for continuous cyclical outpatient and inpatient delivery of cytostatics in strictly controlled amounts; the authors report effective antitumour treatment and increased lifespan. No response rates, survival figures, or sample sizes beyond these individual cases are provided in any abstract. The evidence consists entirely of case reports and a literature review, with no controlled trials.
The abstracts do not specify which drugs were infused, nor do they give concrete survival or response data for any regimen. The claim of effective treatment in the 2024 report is not supported by numerical outcomes. What is missing is any prospective trial, any randomised comparison, any validated patient stratification, and any funding for systematic study of these rare mixed neoplasms.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Thoracic Cancer · 2019 · 3 citations · open access
Multiple metachronous rare primary malignant tumors: A case report
AbstractMultiple primary malignant tumors (MPMTs) are rarely seen among the patients with malignant neoplasms. Moreover, the existence of five MPMTs in the same patient is an extremely rare phenomenon. In this case, a 42-year-old male patient developed five metachronous MPMTs within 16 years and the duration between each malignant tumor shortened with the progression of the disease. Multidisciplinary treatments were used on this patient and he fought against the cancers until the end of his life. Our report provides us with a new awareness of MPMTs, which should be considered when we come across with cancer patients who develop various unexplainable symptoms after the diagnosis of the first neoplasm.
Journal of Medical Case Reports · 2018 · 2 citations · open access
A back-to-back tumor composed of papillary renal cell carcinoma and oncocytoma treated by laparoscopic partial nephrectomy: a case report
AbstractBACKGROUND: Renal oncocytoma is the most common benign renal tumor, and papillary renal cell carcinoma is the second most common histologic subtype of renal cell carcinoma. Renal tumors containing different components such as papillary renal cell carcinoma and oncocytoma are extremely rare. CASE PRESENTATION: A renal mass was incidentally detected in a 52-year-old Korean woman, and a computed tomographic scan showed a 32-mm multicystic mass with some calcifications in the lower pole of the right kidney. She underwent laparoscopic partial nephrectomy without any perioperative complications. We found a papillary renal cell carcinoma and an oncocytoma in a tumor mass. CONCLUSIONS: The possibility of a mixed malignant tumor should be considered while treating benign tumors such as oncocytoma.
Journal of Neurological Surgery Part B Skull Base · 2012 · 1 citations
Temporary Brachytherapy Seed Mesh in the Treatment of a Radiation-Induced Sinonasal Carcinosarcoma: A Case Report and Literature Review
AbstractCarcinosarcoma, a true malignant mixed tumor, is a rare and aggressive tumor that has been described infrequently in the literature since 1864 and has yet to be thoroughly studied or understood. Data and evidence obtained from prospective or randomized trials are lacking, and the treatment of this disease has largely been guided by personal experience and case reviews. The majority of experienced practitioners strongly recommend aggressive and immediate treatment combining surgery, different forms of radiation, and, variably, chemotherapy.
Treatment of patients with multiple primary malignant neoplasms (solid tumors and malignant diseases of the hematopoietic tissue) using systems for independent prolonged infusion therapy. Clinical observations
AbstractStudy of the problem of multiple primary malignant neoplasms (MPMNs) becomes more important and significant in modern clinical oncology. MPMN is a varied group of independent tumors of varying origin located in one or several organs. Due to introduction of single-use elastomeric microinfusion pumps into the clinical practice, continuous cyclical drug outpatient and in-hospital treatment of oncological patients with MPMNs can be performed. Significant successes of specific therapy led to increased lifespan of patients with MPMNs. Prolonged administration of drugs using infusion pump with set velocity allows to deliver cytostatics into the patient’s body in strictly controlled amounts. The article presents 2 clinical cases of effective antitumor treatment of patients with MPMNs using infusion pum
Cambridge University Press eBooks · 2012 · 0 citations
Carcinosarcoma
AbstractCarcinosarcoma, also referred to as “malignant mixed mullerian tumor” or “MMMT,” is a neoplasm composed of malignant-appearing epithelial and mesenchymal elements. Although they can arise in any genital organ, carcinosarcomas are found most frequently in the uterus, where they represent less than 5% of malignant neoplasms. These tumors are increasingly thought of as carcinomas that demonstrate sarcomatoid differentiation. Revisions to the FIGO staging system and the seventh edition of the AJCC Cancer Staging Manual now formally encourage the same staging scheme as for carcinomas: tacit recognition that, in general, carcinosarcomas are closely related to carcinomas. Advances in our understanding of the interplay of tumor biology and epidemiology, along with the increasing use of comprehensive surgical staging and treatment with effective chemotherapeutic agents, have led to the conclusion that carcinosarcoma constitutes a specific clinicopathologic entity, distinct from many other biphasic uterine tumors. The typical carcinosarcoma is a biphasic, mixed epithelial and mesenchymal tumor, the clinical evolution of which is more aggressive than high-grade endometrial carcinoma.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
